Free Trial

Bright Minds Biosciences Q2 2024 Earnings Report

Bright Minds Biosciences logo
$36.50 +0.33 (+0.91%)
As of 03/28/2025 04:00 PM Eastern

Bright Minds Biosciences EPS Results

Actual EPS
-$0.10
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Bright Minds Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Bright Minds Biosciences Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

Remove Ads

Bright Minds Biosciences Earnings Headlines

Bright Minds Biosciences expands Scientific Advisory Board
Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
Bright Minds Biosciences (DRUG) Receives a New Rating from Piper Sandler
See More Bright Minds Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bright Minds Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bright Minds Biosciences and other key companies, straight to your email.

About Bright Minds Biosciences

Bright Minds Biosciences (NASDAQ:DRUG), a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

View Bright Minds Biosciences Profile

More Earnings Resources from MarketBeat